ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ — Acepodia (6976:TT), a clinical…

NEW YORK, Feb. 4, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Dada Nexus Limited (NASDAQ: DADA) between May 11, 2023 and January 8, 2024, both dates inclusive (the “Class Period”), of the important March 11, 2024…

NEW YORK, Feb. 4, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Driven Brands Holdings Inc. (NASDAQ: DRVN) between October 27, 2021 and August 1, 2023, both dates inclusive (the “Class Period”), of the important February…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.